Updated September 2026
Peptide statistics
2026.
Every number on this page has a source you can click. Quote freely with a link — that is what it is for.
Usage
1. About 1 in 8 US adults has used a GLP-1 medicineKFF Health Tracking Poll — roughly 12 percent of adults report ever taking one
2. About 6 percent of US adults were on a GLP-1 at the poll dateKFF — current use, roughly half of ever-users
3. Weight loss is the fastest-growing reason for useKFF — outpacing diabetes as the stated purpose among new users
Prices — September 2026 index
4. Cheapest verified compounded semaglutide: $139 a month all-inUS Peptide Price Index, mandatory fees included
5. The same molecule spans a 3x price spread between clinics$139 to $400+ a month for compounded semaglutide — live table
6. Advertised headlines understate real bills by up to $99 a monthMandatory membership fees excluded from ads — methodology
7. Compounded tirzepatide programs start near $300 a monthIndex — and the bill grows with monthly dose escalation
8. Brand self-pay floors: Zepbound vials $349, Wegovy $499Maker channels LillyDirect and NovoCare — Zepbound, Wegovy pages
9. Pharmacy list price runs 2 to 4x the realistic cash price$1,000 to $1,350 a month at list versus $349 to $650 through maker programs
10. Sermorelin is the cheapest prescription peptide lane: from about $50 a monthPrice index overview table
11. NAD+ at home costs a fraction of IV loungesSubcutaneous programs $100 to $300 a month versus $300+ per single IV session — index
Regulatory status
12. Only a handful of therapeutic peptides carry FDA approval for their popular usesSemaglutide, tirzepatide, liraglutide, tesamorelin, bremelanotide among them — full list on the approval tracker
13. BPC-157, TB-500 and most "healing" peptides have zero FDA approvalSold as research chemicals; human use is off-label territory at best — safety guide
14. In July 2026 an FDA advisory panel voted to allow pharmacy compounding of BPC-157, TB-500, KPV and MOTS-cFinal rule expected around mid-2027 — live status tracker
15. Retatrutide remains trial-only: no legal retail purchase existsEverything sold online as "reta" is unregulated — approval tracker
16. FDA warning letters hit peptide sellers repeatedly through 2026March and August 2026 letters named retatrutide, SS-31 and tesamorelin sellers marketing research chemicals for human use
17. BPC-157 is banned in tested sportWADA prohibited list — a positive test ends careers regardless of legality elsewhere
Trial results
18. Semaglutide 2.4 mg: about 15 percent average body-weight lossSTEP-1 trial, 68 weeks, versus 2.4 percent on placebo
19. Tirzepatide 15 mg: about 20 percent average lossSURMOUNT-1, 72 weeks — the strongest approved result
20. Retatrutide phase 2: about 24 percent at the top dose48 weeks — phase 3 TRIUMPH program running, results tracked on our tracker
21. Tirzepatide is FDA-approved for sleep apneaThe first drug approval for OSA in obesity — detail on the sleep page
22. Tesamorelin is FDA-approved to cut visceral fatIn HIV-associated lipodystrophy — the only GH-axis peptide with a hard approval
23. Weight returns when GLP-1 stops: about two-thirds of the loss within a yearSTEP-1 extension — the reason physicians treat it as ongoing therapy, not a course
The market
24. Google searches for "peptide calculator" tripled in under a yearPublic Google trend and volume data — the do-it-yourself wave in one number
25. Telehealth is the default door: most compounded programs never see an officeEvery program in our index ships after an online visit — index
26. A major pharmacy chain's site now runs a peptide content and telehealth armThe category has left the biohacker corner and entered mainstream retail
Cite any number with a link to this page. Corrections: hello@uspeptideboard.com. Updated with each monthly price-index edition.